Medical Xpress

NOVEMBER 28, 2022

We have vaccines to boost our immune response to SARS-CoV-2, the virus that causes COVID. We have medicines you can take at home (and in hospital) to treat COVID. Now researchers are trialing something new.

Immune Response 71

Immune Response Vaccination Vaccine Medicine 71

Cloudbyz

JULY 31, 2024

The landscape of modern medicine is rapidly evolving, driven by groundbreaking advancements in diagnostics. This revolution is enabling the growth of innovative biomarker-based precision medicine and cell and gene therapy, transforming both clinical research and post-market care.

Gene Therapy 52

Gene Therapy Gene Medicine In-Vitro 52

XTalks

FEBRUARY 19, 2024

In a recent study published by Weill Cornell Medicine in the Journal of Infectious Diseases , researchers have reported the potential of Moderna’s experimental mRNA vaccine in protecting adults against CMV, which could potentially also stop the transmission of the virus from mothers to their infants during pregnancy.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

pharmaphorum

OCTOBER 12, 2022

Genomic medicine is a rapidly growing space in which researchers use the information in a person’s genes to identify and administer medical treatment.”. The evolving field of genomic medicine. There are two components to genomic medicine, known as the payload and the vector.

Genome 105

Genome Genomics Medicine Development 105

Scienmag

JUNE 27, 2021

The first human trial has shown no obvious side effects and a good immune response. Researchers based […]. Hiroshi Kiyono, CC BY 4.0 A new vaccine to protect against deadly cholera has been made by grinding up genetically modified grains of rice.

Vaccination 72

Vaccination Vaccine Immune Response Trials 72

Worldwide Clinical Trials

JUNE 21, 2024

The 2024 ASCO Annual Meeting from the American Society of Clinical Oncology is a fantastic platform for clinical researchers to discuss the latest advancements and challenges in oncology research. Microenvironment Management : Optimizing the tumor microenvironment to enhance TIL efficacy remains a critical focus of research efforts.

Antibody 162

Antibody Clinical Trials Clinical Trials In-Vitro 162

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. This marks the second time one of Janssen’s HIV vaccines failed after another showed disappointing results in the Phase IIb Imbokodo trial in August 2021.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

Pharmaceutical Technology

APRIL 28, 2023

Therini Bio will use part of the funds to advance its potential first-in-class investigational antibody, THN391, into clinical trials. THN391 binds the inflammation-driving component of fibrin, known for activating the immune responses in neurodegenerative and ophthalmologic diseases.

Development 130

Development Immune Response Clinical Trials Clinical Trials 130

XTalks

SEPTEMBER 21, 2023

announced that the first participant has been dosed in a new Phase I trial for an innovative HIV vaccine candidate, VIR-1388. The trial’s primary objective is to assess the safety of VIR-1388 and its capacity to stimulate a specific immune response against HIV in study participants. Vir Biotechnology, Inc.,

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

The Pharma Data

MARCH 31, 2022

A Phase 2 clinical trial evaluating various additional COVID-19 booster shots has begun enrolling adult participants in the United States. The study, known as the COVID-19 Variant Immunologic Landscape (COVAIL) trial, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Immune Response 52

pharmaphorum

NOVEMBER 25, 2022

While the shot is still in preclinical development, if it works in human trials it could raise the prospect of eventually sidestepping the annual scramble to guess the most likely strains to be circulating in the following flu season, and protect against future flu pandemics.

Vaccination 105

Vaccination Vaccine Research Immune Response 105

XTalks

OCTOBER 1, 2024

Thomas Langenickel, Chief Medical Officer at Ethris , we explored the implications of an innovative method and what it could mean for the future of respiratory medicine. This magazine immerses you in a world where industry leaders, patient advocates and top researchers converge to provide the most insightful perspectives on clinical trials.

Development 52

Development Drugs Immune Response Protein 52

XTalks

OCTOBER 12, 2021

The experimental arthritis vaccine was developed by researchers at the University of Toledo (UToledo) and is a major breakthrough for rheumatoid arthritis and other autoimmune diseases as well. The vaccine was tested in rats and showed strong, immediate and long-lasting immune responses to confer protection against the disease.

Vaccination 102

Vaccination Vaccine Research Immune Response 102

XTalks

DECEMBER 29, 2023

Reese, executive vice president of Research and Development at Amgen, in the company’s press release. Tarlatamab is an investigational drug currently undergoing clinical trials to assess its efficacy in patients with two distinct types of neuroendocrine cancer: SCLC and neuroendocrine prostate cancer (NEPC).

Clinical Trials 112

Clinical Trials Clinical Trials FDA Approval Trials 112

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. Freenome persists in getting strong financial support for its development work, with USD 270 million in new funds to push its cancer-detecting blood test via clinical trials and across the FDA’s finish line.

Vaccination 53

Vaccination Vaccine Research Trials 53

pharmaphorum

SEPTEMBER 30, 2020

This first data comes from a descriptive analysis from the seamless phase 1/2/3 trial that Regeneron hopes will hurry the medicine dubbed REGN-COV2 to market. The ongoing double-blind trial measures the effect of adding REGN-COV2 to usual standard of care, compared with usual standard of care. There were no deaths in the trial.

Antibody 135

Antibody Immune Response Trials Protein 135

The Pharma Data

JANUARY 25, 2021

Regeneron’s monoclonal antibody cocktail reduced medical visits for COVID-19 patients who had not been hospitalized by almost 50 percent, according to interim clinical trial results reported by researchers at the company. And safety outcomes were similar in the REGN-COV2 dose groups and the placebo group. Source link.

Antibody 52

Antibody Immune Response Clinical Trials Clinical Trials 52

Advarra

JANUARY 11, 2024

The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. While mRNA usage has played several roles in clinical research , oncology researchers in particular are eager to explore the possibilities of mRNA-based cancer vaccines.

Vaccination 52

Vaccination Vaccine Protein Antibody 52

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. The Companies expect interim results from this trial in the third quarter of 2021. About the Phase 1/2 clinical trial.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

The Pharma Data

DECEMBER 7, 2020

In an early-stage clinical trial with 65 volunteers in the United States, an experimental vaccine triggered strong immune responses to a wide range of flu virus strains and subtypes. The immune responses lasted at least 18 months, according to the researchers at Mount Sinai Health System, in New York City.

Vaccination 52

Vaccination Vaccine Scientist Immune Response 52

Pfizer

FEBRUARY 16, 2023

These study participants, representing approximately half of the total recruited participants in the trial, are being discontinued following violations of Good Clinical Practice (GCP) at certain clinical trial sites run by a third-party clinical trial site operator.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccination Vaccine 76

The Pharma Data

DECEMBER 10, 2020

Food and Drug Administration and the European Medicines Agency. NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the New England Journal of Medicinehas published safety and final efficacy results from the pivotal Phase 3 trial of BNT162b2, their mRNA-based COVID-19 vaccine candidate. Jansen, Ph.D.,

Vaccination 52

Vaccination Vaccine Trials Medicine 52

pharmaphorum

FEBRUARY 18, 2021

The researchers will also inoculate them with the version of the virus that has been circulating in the UK since the start of the pandemic, rather than one of the new, more transmissible variants, as an added safety precaution. million ($47 million) in funding.

Vaccination 118

Vaccination Vaccine Immune Response Trials 118

Cloudbyz

MARCH 5, 2024

In the intricate dance of drug discovery and development, two protagonists emerge as the cornerstones of modern medicine: biologics and small molecules. They are often used to mimic or enhance natural biological processes, such as immune responses. Their small size allows them to distribute widely throughout the body.

Development 97

Development Drugs Manufacturing Immune Response 97

Sciensano

JULY 5, 2023

This symposium will be an opportunity to: discover the immune response of different vulnerable and non-vulnerable populations (morning) and to learn more about how serosurveillance has been managed in other European countries and how to remain vigilant in the future (afternoon).

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52

The Pharma Data

SEPTEMBER 4, 2020

The data, published in Nature Medicine, show that the investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited an immune response as demonstrated by neutralising antibodies and prevented severe clinical disease, including weight loss, pneumonia and mortality, the firm said. Source link. .

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52

Olympian Clinical Research

NOVEMBER 30, 2023

Vitiligo, characterized by the loss of skin pigment and the formation of white patches, has been a subject of medical intrigue and research for decades. The exact cause of vitiligo is still under investigation, with factors like genetics , autoimmune responses, and environmental triggers all playing potential roles.

Clinical Research 52

Clinical Research Clinical Trials Clinical Trials Immune Response 52

The Pharma Data

JANUARY 22, 2021

Regeneron’s monoclonal antibody cocktail reduced medical visits for COVID-19 patients who had not been hospitalized by almost 50 percent, according to interim clinical trial results reported by researchers at the company. The lead author, David Weinreich, and several co-authors work for Regeneron. 24, 2020 ). Martin Berman-Gorvine.

Antibody 52

Antibody Immune Response Clinical Trials Clinical Trials 52

pharmaphorum

FEBRUARY 18, 2021

Researchers from the University of Texas Medical Branch based their findings on lab tests using SARS-CoV-2 coronaviruses that were genetically engineered to have the same mutations as those in the strain that is causing scientists so much concern.

Immune Response 52

Immune Response Genetic Engineering Vaccination Vaccine 52

Camargo

DECEMBER 13, 2021

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. One common characteristic for most if not all biologics is the triggering of an immune response or anti-drug antibodies.

Development 161

Development Production Immune Response Licensing 161

Scienmag

APRIL 11, 2021

For the first time, researchers led by SU2C “Dream Team” show how CD40 agonist drives an immune response to hard-to-penetrate tumors PHILADELPHIA–Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other (..)

Immune Response 40

Immune Response Drugs Research Clinical Trials 40

The Pharma Data

APRIL 8, 2021

AstraZeneca will share updates from the Company’s innovative early oncology pipeline across multiple strategic platforms during the virtual American Association of Cancer Research (AACR) Annual Meeting, 10 to 15 April 2021. A pooled analysis of interstitial lung disease data in patients treated with Enhertu across eight cancer trials.

DNA 52

DNA Medicine Genome Genomics 52

The Pharma Data

DECEMBER 17, 2020

NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , 17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Medicine Production Trials 52

The Pharma Data

DECEMBER 23, 2020

Joseph Kim , President and CEO of INOVIO, said, “We are very pleased to share peer-reviewed Phase 1 clinical data for INO-4800 published in The Lancet’s EClinicalMedicine , and are grateful for the support of all participants and investigator staff involved in the clinical trial.” . mg and 2.0 mg and 2.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

The Pharma Data

DECEMBER 29, 2020

As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes. The analysis was prospectively designed to focus on patients who had not yet mounted their own immune response to SARS-CoV-2 (i.e., Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Trials Production Clinical Trials 52

The Pharma Data

NOVEMBER 16, 2020

Those figures alone show there is a “huge need” for a vaccine, said Gary Pickard, one of the researchers on the new study. But beyond that, once HSV invades the body, it’s there to stay, said Pickard, a professor of neuroscience at the University of Nebraska-Lincoln School of Veterinary Medicine and Biomedical Sciences.

Vaccination 52

Vaccination Vaccine Immune Response Genetics 52

Delveinsight

AUGUST 26, 2021

The company then utilizes the de-identified records to improve the design of clinical trials and quality of life measurements. Currently, AllStripes partners with more than 30 patient advocacy organizations to back research into 40 different conditions by gathering data from more than 3,000 users to date.

Vaccination 98

Vaccination Vaccine Gene Therapy RNA 98